Literature DB >> 22766220

Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.

Daniel Weisdorf1, Mei-Jie Zhang, Mukta Arora, Mary M Horowitz, J Douglas Rizzo, Mary Eapen.   

Abstract

We studied graft-versus-host disease (GVHD) on relapse, transplant-related mortality (TRM), disease-free survival (DFS), and overall survival (OS) after allogeneic transplantation for acute myelogenous leukemia (AML) (n = 4224) and myelodysplastic syndrome (MDS) (n = 1517) in 4 groups: without GVHD, acute GVHD (aGVHD) alone, chronic GVHD (cGVHD) alone, and aGVHD + cGVHD. Examining GVHD as a time-dependent covariate, after myeloablative conditioning (MAC), cGVHD and aGVHD + cGVHD were associated with lower relapse (P < .002). TRM was higher in all GVHD groups (P < .0001); DFS and OS were lower with aGVHD ± cGVHD (P < .0001). After reduced-intensity conditioning (RIC), relapse was lower in all GVHD groups (P < .0001); TRM was increased and DFS and OS were reduced with any GVHD (P < .0001). In those surviving disease-free (≥1-year) after MAC, relapse risks were similar in all groups and TRM was higher with any GVHD (P < .0001). DFS and OS were lower with cGVHD and aGVHD + cGVHD (P < .0006). After RIC, relapse was lower (P = .009) and TRM higher (P = .002) only with aGVHD + cGVHD. DFS was similar in all groups and OS worse with aGVHD + cGVHD. After MAC, GVHD has an adverse effect on TRM with early modest augmentation of GVHD-associated graft-versus-leukemia (GVL). With RIC, GVHD-associated GVL may be important in limiting both early and late leukemia recurrence.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22766220      PMCID: PMC3472079          DOI: 10.1016/j.bbmt.2012.06.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  20 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.

Authors:  Yoshihiro Inamoto; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; Edus H Warren; H Joachim Deeg; Rainer F Storb; Frederick R Appelbaum; Barry E Storer; Paul J Martin
Journal:  Blood       Date:  2011-06-01       Impact factor: 22.113

3.  Non-parametric inference for cumulative incidence functions in competing risks studies.

Authors:  D Y Lin
Journal:  Stat Med       Date:  1997-04-30       Impact factor: 2.373

4.  Cure of hematologic neoplasia with transplantation of marrow from identical twins.

Authors:  A Fefer; C D Buckner; E D Thomas; M A Cheever; R A Clift; H Glucksberg; P E Neiman; R Storb
Journal:  N Engl J Med       Date:  1977-07-21       Impact factor: 91.245

5.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

6.  Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.

Authors:  Daniel J Weisdorf; Claudio Anasetti; Joseph H Antin; Nancy A Kernan; Craig Kollman; David Snyder; Effie Petersdorf; Gene Nelson; Philip McGlave
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

7.  Graft-versus-leukemia reactions after bone marrow transplantation.

Authors:  M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

8.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Authors:  Christoph Kahl; Barry E Storer; Brenda M Sandmaier; Marco Mielcarek; Michael B Maris; Karl G Blume; Dietger Niederwieser; Thomas R Chauncey; Stephen J Forman; Edward Agura; Jose F Leis; Benedetto Bruno; Amelia Langston; Michael A Pulsipher; Peter A McSweeney; James C Wade; Elliot Epner; Finn Bo Petersen; Wolfgang A Bethge; David G Maloney; Rainer Storb
Journal:  Blood       Date:  2007-06-26       Impact factor: 22.113

10.  Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program.

Authors:  Sergio Giralt; Brent Logan; Douglas Rizzo; Mei-Jie Zhang; Karen Ballen; Christos Emmanouilides; Rajneesh Nath; Pablo Parker; David Porter; Brenda Sandmaier; Edmund K Waller; Juliet Barker; Steven Pavletic; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2007-05-24       Impact factor: 5.742

View more
  46 in total

1.  The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Marie Thérèse Rubio; Myriam Labopin; Didier Blaise; Gerard Socié; Rafael Rojas Contreras; Patrice Chevallier; Miguel A Sanz; Stéphane Vigouroux; Anne Huynh; Avichai Shimoni; Claude-Eric Bulabois; Nerea Caminos; Lucía López-Corral; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

2.  CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.

Authors:  Roni Tamari; Stephen S Chung; Esperanza B Papadopoulos; Ann A Jakubowski; Patrick Hilden; Sean M Devlin; Jenna D Goldberg; Miguel-Angel Perales; Doris M Ponce; Craig S Sauter; Molly A Maloy; Dara Y Herman; Virginia Klimek; James W Young; Richard J O'Reilly; Sergio A Giralt; Hugo Castro-Malaspina
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-14       Impact factor: 5.742

3.  Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

Authors:  Christopher G Kanakry; Hua-Ling Tsai; Javier Bolaños-Meade; B Douglas Smith; Ivana Gojo; Jennifer A Kanakry; Yvette L Kasamon; Douglas E Gladstone; William Matsui; Ivan Borrello; Carol Ann Huff; Lode J Swinnen; Jonathan D Powell; Keith W Pratz; Amy E DeZern; Margaret M Showel; Michael A McDevitt; Robert A Brodsky; Mark J Levis; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik
Journal:  Blood       Date:  2014-10-14       Impact factor: 22.113

4.  Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia.

Authors:  Michael Boyiadzis; Mukta Arora; John P Klein; Anna Hassebroek; Michael Hemmer; Alvaro Urbano-Ispizua; Joseph H Antin; Brian J Bolwell; Jean-Yves Y Cahn; Mitchell S Cairo; Corey S Cutler; Mary E Flowers; Robert P Gale; Roger Herzig; Luis M Isola; David A Jacobsohn; Madan H Jagasia; Thomas R Klumpp; Stephanie J Lee; Effie W Petersdorf; Stella Santarone; Stephen R Spellman; Harry C Schouten; Leo F Verdonck; John R Wingard; Daniel J Weisdorf; Mary M Horowitz; Steven Z Pavletic
Journal:  Clin Cancer Res       Date:  2014-10-27       Impact factor: 12.531

5.  Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  F Baron; M Labopin; D Blaise; L Lopez-Corral; S Vigouroux; C Craddock; M Attal; P Jindra; H Goker; G Socié; P Chevallier; P Browne; A Sandstedt; R F Duarte; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

6.  Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.

Authors:  R Vrhovac; M Labopin; F Ciceri; J Finke; E Holler; J Tischer; B Lioure; J Gribben; L Kanz; D Blaise; P Dreger; G Held; R Arnold; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

7.  Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects.

Authors:  Rainer Storb; Boglarka Gyurkocza; Barry E Storer; David G Maloney; Mohamed L Sorror; Marco Mielcarek; Paul J Martin; Brenda M Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-14       Impact factor: 5.742

Review 8.  Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how.

Authors:  John Magenau; Daniel R Couriel
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 9.  Graft-versus-host disease: why have we not made more progress?

Authors:  Samantha M Jaglowski; Steven M Devine
Journal:  Curr Opin Hematol       Date:  2014-03       Impact factor: 3.284

10.  Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.

Authors:  Kinjal Sanghavi; Anthony Wiseman; Mark N Kirstein; Qing Cao; Richard Brundage; Kyle Jensen; John Rogosheske; Andy Kurtzweil; Janel Long-Boyle; John Wagner; Erica D Warlick; Claudio G Brunstein; Daniel J Weisdorf; Pamala A Jacobson
Journal:  Transl Res       Date:  2016-03-31       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.